Archives of Dermatological Research

, Volume 305, Issue 2, pp 91–98 | Cite as

Recommendations for detection of individual risk for comorbidities in patients with psoriasis

  • Johannes WohlrabEmail author
  • Gabriele Fiedler
  • Sascha Gerdes
  • Alexander Nast
  • Sandra Philipp
  • Marc A. Radtke
  • Diamant Thaçi
  • Wolfgang Koenig
  • Andreas F. H. Pfeiffer
  • Martin Härter
  • Michael P. Schön
Mini Review


Since the pathogenesis of psoriasis vulgaris is now understood as a T cell mediated systemic auto-immune disease, the awareness for the potential systemic implications of the chronic active inflammation has grown. By evaluation of patient registries and study data, several complexes of comorbidities could be identified in recent years, albeit not all of them being clinically relevant. Comorbidity in this context will be defined as two or more diagnostically distinguished medical conditions existing simultaneously, but without a causal link. Nevertheless, there is some strong indication for pathogenetic link between some specified comorbidities and psoriasis at molecular and immunological level. The need for an interdisciplinary assessment of the potential interrelation is obvious. In order to detect the individual risk for comorbidities in patients with moderate to severe psoriasis and to recommend the course of action, a checklist has been developed at an interdisciplinary level that is reduced to the quintessential points for the use in daily practice.


Psoriasis Comorbidities 



The initiative group would like to thank Pfizer Germany GmbH for financially supporting the organisational framework of the project. Pfizer has had no content-related influence on the project. Further, the authors would like to thank the German Cardiac Society, the German Society of Endocrinology as well as the German Association for Psychiatry and Psychotherapy for their support, advice and co-operation.

Conflict of interest

The following authors have received fees for lecturing and/or consulting, and/or received funding for scientific projects or clinical studies from sponsors that market products for indications mentioned in the article: JW: Abbott, Biogen-Idec, Janssen-Cilag, Leo, MSD, Novartis, Pfizer; SG: Pfizer; AN: Abbott, Bayer Health Care, Janssen-Cilag, Pfizer; MR: Pfizer; DT: Abbott, Astellas, Biogen-Idec, Janssen-Cilag, Leo, MSD, Novartis, Pfizer. GF, SP, WK, AP, MH and MS declare to have no conflict of interest.


  1. 1.
    Abou-Raya A, Abou-Raya S (2006) Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 5:331–337PubMedCrossRefGoogle Scholar
  2. 2.
    Abraham JM, Cho L (2010) The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease? Cleve Clin J Med 77:911–918PubMedCrossRefGoogle Scholar
  3. 3.
    Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 163:586–592PubMedCrossRefGoogle Scholar
  4. 4.
    Ahlehoff O (2011) Psoriasis and cardiovascular disease: epidemiological studies. Dan Med Bull 58:B4347PubMedGoogle Scholar
  5. 5.
    Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRefGoogle Scholar
  6. 6.
    Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRefGoogle Scholar
  7. 7.
    Alsufyani MA, Golant AK, Lebwohl M (2010) Psoriasis and the metabolic syndrome. Dermatol Ther 23:137–143PubMedCrossRefGoogle Scholar
  8. 8.
    Angeli V, Llodra J, Rong JX, Satoh K, Ishii S, Shimizu T, Fisher EA, Randolph GJ (2004) Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21:561–574PubMedCrossRefGoogle Scholar
  9. 9.
    Ascaso JF, Millan J, Mateo-Gallego R, Ruiz A, Suarez-Tembra M, Borrallo RM, Zambon D, Gonzalez-Santos P, Peres-de-Juan M, Ros E (2011) Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population. Eur J Intern Med 22:177–181PubMedCrossRefGoogle Scholar
  10. 10.
    Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162:633–636PubMedCrossRefGoogle Scholar
  11. 11.
    Benesch L, Bjarnason-Wehrens B, Cordes C, Franz I-W, Grunze M, Gysan D, Hoberg E, Hoffmann K, Klein G, Miche E, Schröder K, Theisen F, Tönnesmann U, Völler H, Volger E, Willemsen D, Wirth A, Witt T (2003) Umsetzungsempfehlung der Leitlinie arterielle Hypertonie für die kardiologische Rehabilitation. Herzmedizin 20:209–222Google Scholar
  12. 12.
    Brazzelli V, Grasso V, Fornara L, Moggio E, Gamba G, Villani S, Borroni G (2010) Homocysteine, vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity. Int J Immunopathol Pharmacol 23:911–916PubMedGoogle Scholar
  13. 13.
    Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA (1998) The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project. Alcohol Use Disorders Identification Test. Arch Intern Med 158:1789–1795PubMedCrossRefGoogle Scholar
  14. 14.
    Cakmak SK, Gul U, Kilic C, Gonul M, Soylu S, Kilic A (2009) Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol 23:300–303PubMedCrossRefGoogle Scholar
  15. 15.
    Church T (2011) Exercise in obesity, metabolic syndrome, and diabetes. Prog Cardiovasc Dis 53:412–418PubMedCrossRefGoogle Scholar
  16. 16.
    Cohen AD, Weitzman D, Dreiher J (2010) Psoriasis and hypertension: a case-control study. Acta Derm Venereol 90:23–26PubMedCrossRefGoogle Scholar
  17. 17.
    Dauden E, Castaneda S, Suarez C, Garcia-Campayo J, Blasco AJ, Aguilar MD, Ferrandiz C, Puig L, Sanchez-Carazo JL (2012) Integrated approach to comorbidity in patients with psoriasis. Actas Dermosifiliogr 103(Suppl 1):1–64PubMedGoogle Scholar
  18. 18.
    DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194PubMedCrossRefGoogle Scholar
  19. 19.
    Favato G (2008) High incidence of smoking habit in psoriatic patients. Am J Med 121:e17PubMedCrossRefGoogle Scholar
  20. 20.
    Francis K (1998) The burden of physical inactivity & cardiovascular heart disease. Compr Ther 24:87–92PubMedGoogle Scholar
  21. 21.
    Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, Jarratt MT, Krueger JG, Ridker PM, Stone N, Roberts WC (2008) AJC editor’s consensus: psoriasis and coronary artery disease. Am J Cardiol 102:1631–1643PubMedCrossRefGoogle Scholar
  22. 22.
    Fortes C, Mastroeni S, Leffondre K, Sampogna F, Melchi F, Mazzotti E, Pasquini P, Abeni D (2005) Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 141:1580–1584PubMedCrossRefGoogle Scholar
  23. 23.
    Gerdes S, Zahl VA, Weichenthal M, Mrowietz U (2010) Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 220:38–43PubMedCrossRefGoogle Scholar
  24. 24.
    Gisondi P, Farina S, Giordano MV, Girolomoni G (2010) Usefulness of the framingham risk score in patients with chronic psoriasis. Am J Cardiol 106:1754–1757PubMedCrossRefGoogle Scholar
  25. 25.
    Goldstein LB, Whitsel LP, Meltzer N, Schoeberl M, Birnbaum J, Nelson S, Gardner TJ, Yancy CW, Gibbons RJ, Sacco RL, Hiratzka L (2011) American Heart Association and nonprofit advocacy: past, present, and future. A policy recommendation from the American Heart Association. Circulation 123:816–832PubMedCrossRefGoogle Scholar
  26. 26.
    Guinhouya BC, Samouda H, Zitouni D, Vilhelm C, Hubert H (2011) Evidence of the influence of physical activity on the metabolic syndrome and/or on insulin resistance in pediatric populations: a systematic review. Int J Pediatr Obes 6:361–388PubMedCrossRefGoogle Scholar
  27. 27.
    Härter MC (2000) Psychische Störungen bei körperlichen Erkrankungen. Psychother Psychosom Med Psychol 50:274–286PubMedCrossRefGoogle Scholar
  28. 28.
    Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA (2007) Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health 7:220PubMedCrossRefGoogle Scholar
  29. 29.
    Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J (2010) Body mass index, waist circumference and waist: hip ratio as predictors of cardiovascular risk—a review of the literature. Eur J Clin Nutr 64:16–22PubMedCrossRefGoogle Scholar
  30. 30.
    Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132–140PubMedCrossRefGoogle Scholar
  31. 31.
    Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM (2012) Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol in pressGoogle Scholar
  32. 32.
    Kimball AB, Wu Y (2009) Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol 48:1147–1156PubMedCrossRefGoogle Scholar
  33. 33.
    Lloyd LJ, Langley-Evans SC, McMullen S (2012) Childhood obesity and risk of the adult metabolic syndrome: a systematic review. Int J Obes (Lond) 36:1–11CrossRefGoogle Scholar
  34. 34.
    Mlinar B, Marc J (2011) Review: new insights into adipose tissue dysfunction in insulin resistance. Clin Chem Lab Med 49:1925–1935PubMedCrossRefGoogle Scholar
  35. 35.
    Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B (2012) S3—Guidelines on the treatment of psoriasis vulgaris. Update. J Dtsch Dermatol Ges 10(Suppl 2):S1–S95Google Scholar
  36. 36.
    Owen DR, Lindsay AC, Choudhury RP, Fayad ZA (2011) Imaging of atherosclerosis. Annu Rev Med 62:25–40PubMedCrossRefGoogle Scholar
  37. 37.
    Padayachee L, Rodseth RN, Biccard BM (2009) A meta-analysis of the utility of C-reactive protein in predicting early, intermediate-term and long term mortality and major adverse cardiac events in vascular surgical patients. Anaesthesia 64:416–424PubMedCrossRefGoogle Scholar
  38. 38.
    Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Honigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B (2009) European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23(Suppl 2):1–70PubMedCrossRefGoogle Scholar
  39. 39.
    Pereira IA, Borba EF (2008) The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly 138:534–539PubMedGoogle Scholar
  40. 40.
    Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC (2010) Lipid disturbances in psoriasis: an update. Mediators Inflamm pii: 535612Google Scholar
  41. 41.
    Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Le Maitre M, Richard-Lallemand MA, Ortonne JP (2010) Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 24(Suppl 2):23–30PubMedCrossRefGoogle Scholar
  42. 42.
    Qureshi AA, Dominguez PL, Choi HK, Han J, Curhan G (2010) Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol 146:1364–1369PubMedCrossRefGoogle Scholar
  43. 43.
    Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hobbs R, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Funck-Brentano C, Poldermans D, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology and the European Atherosclerosis Society. Eur Heart J 32:1769–1818PubMedCrossRefGoogle Scholar
  44. 44.
    Reuter K, Harter M (2011) Screening und Diagnostik komorbider psychischer Storungen bei korperlichen Erkrankungen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 54:22–28PubMedCrossRefGoogle Scholar
  45. 45.
    Schäfer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M (2011) Epidemiologie der Psoriasis in Deutschland-Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Gesundheitswesen 73:308–313PubMedCrossRefGoogle Scholar
  46. 46.
    Schmieder RE (2010) End organ damage in hypertension. Dtsch Ärztebl Int 107:866–873PubMedGoogle Scholar
  47. 47.
    Shimada K (2009) Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J 73:994–1001PubMedCrossRefGoogle Scholar
  48. 48.
    Szepietowski JC, Bielicka E, Wasik F, Kopec W, Szepietowski T (2000) Microalbuminuria as a subclinical marker of renal impairment in subjects with psoriasis vulgaris. J Eur Acad Dermatol Venereol 14:513–514PubMedCrossRefGoogle Scholar
  49. 49.
    Whitworth JA (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983–1992PubMedCrossRefGoogle Scholar
  50. 50.
    Whooley MA, Avins AL, Miranda J, Browner WS (1997) Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 12:439–445PubMedCrossRefGoogle Scholar
  51. 51.
    Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL (2011) C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med 123:114–119PubMedCrossRefGoogle Scholar

Related articles recently published in Archives of Dermatological Research (selected by the journal’s editorial staff):

  1. 52.
    Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Ackermann H, Boehncke WH, Ochsendorf FR (2011) Changes in the sex hormone profile of male patients with moderate-to-severe plaque-type psoriasis under systemic therapy: results of a prospective longitudinal pilot study. Arch Dermatol Res 303:417–424PubMedCrossRefGoogle Scholar
  2. 53.
    Cheng J, Kuai D, Zhang L, Yang X, Qiu B (2012) Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res 304:119–125PubMedCrossRefGoogle Scholar
  3. 54.
    De Marco G, Cattaneo A, Battafarano N, Lubrano E, Carrera CG, Marchesoni A (2012) Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. Arch Dermatol Res 304:719–726PubMedCrossRefGoogle Scholar
  4. 55.
    Janowski K, Steuden S, Pietrzak A, Krasowska D, Kaczmarek L, Gradus I, Chodorowska G (2012) Social support and adaptation to the disease in men and women with psoriasis. Arch Dermatol Res 304:421–432PubMedCrossRefGoogle Scholar
  5. 56.
    Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Dauden E, Gisondi P, Iversen L, Kemeny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303:1–10PubMedCrossRefGoogle Scholar
  6. 57.
    Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B (2012) German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 304:87–113PubMedCrossRefGoogle Scholar
  7. 58.
    Romani J, Caixas A, Ceperuelo-Mallafre V, Carrascosa JM, Ribera M, Rigla M, Vendrell J, Luelmo J (2012) Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch Dermatol Res. doi:  10.1007/s00403-012-1306-5 [Epub ahead of print]
  8. 59.
    Thorslund K, Amatya B, Dufva AE, Nordlind K (2012) The expression of serotonin transporter protein correlates with the severity of psoriasis and chronic stress. Arch Dermatol Res. doi:  10.1007/s00403-012-1303-8 [Epub ahead of print]
  9. 60.
    Velez NF, Wei-Passanese EX, Husni ME, Mody EA, Qureshi AA (2012) Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res 304:7–13PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Johannes Wohlrab
    • 1
    Email author
  • Gabriele Fiedler
    • 2
  • Sascha Gerdes
    • 3
  • Alexander Nast
    • 4
  • Sandra Philipp
    • 5
  • Marc A. Radtke
    • 6
  • Diamant Thaçi
    • 7
  • Wolfgang Koenig
    • 8
  • Andreas F. H. Pfeiffer
    • 9
  • Martin Härter
    • 10
  • Michael P. Schön
    • 11
  1. 1.Department of Dermatology and VenereologyMartin-Luther-University Halle-WittenbergHalle (Saale)Germany
  2. 2.Dermatological practiceWeißenfelsGermany
  3. 3.Department of DermatologyAllergology and Venereology (Psoriasis-Centre) of University Medical Centre Schleswig-HolsteinKielGermany
  4. 4.Division of Evidence Based Medicine, University Clinic and Policlinic of Dermatology, Allergology and VenereologyCharité, University Medicine BerlinBerlinGermany
  5. 5.University Clinic and Policlinic of Dermatology, Allergology and VenereologyCharité, University Medicine BerlinBerlinGermany
  6. 6.Institute for Health Services Research in Dermatology and NursingUniversity Medical Centre Hamburg-EppendorfHamburgGermany
  7. 7.Department of Dermatology, Venereology and AllergologyJ.W. Goethe University Hospital and Faculty of Medicine Frankfurt am MainFrankfurtGermany
  8. 8.Department of Internal Medicine II—Cardiology, Centre for Internal MedicineUniversity of UlmUlmGermany
  9. 9.Endocrinology, Diabetes and Nutrition MedicineCharité, University Medicine BerlinBerlinGermany
  10. 10.Department of Medical Psychology, Centre for Psychosocial MedicineUniversity Medical Centre Hamburg-EppendorfHamburgGermany
  11. 11.Department of Dermatology, Venereology and AllergologyUniversity Medical Centre GöttingenGöttingenGermany

Personalised recommendations